SELLAS Life Sciences Group, Inc. has been granted Fast Track Designation by the U.S. Food and Drug Administration for its CDK9 inhibitor, SLS009, targeted at treating relapsed/refractory

Biocytogen Pharmaceuticals Co., Ltd, a global biotech firm focused on groundbreaking antibody therapeutics, has revealed an Exclusive Option and License Agreement

The Menarini Group, a prominent pharmaceutical and diagnostics company, together with its subsidiary Stemline Therapeutics, and Insilico Medicine, a biotechnology company utilizing artificial intelligence

Illumina Inc. has recently forged a partnership with Janssen Research & Development, LLC to advance the development of Illumina's unique molecular residual disease assay.

Omniose, a preclinical biotechnology company, has recently revealed an exclusive collaboration agreement with AstraZeneca to investigate potential vaccines

Turbine, a notable biological simulation company specializing in the creation of a platform for simulating human biology in silico, has recently disclosed a collaboration with AstraZeneca, a global biopharmaceutical company

Merck, a prominent science and technology company, has recently entered into a licensing agreement with Inspirna, Inc. based in New York, NY, for ompenaclid, an innovative oral inhibitor targeting

INOVIO, a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, recently disclosed a clinical collaboration and supply agreement with Coherus BioSciences.

AC Immune SA has released a positive update on its active immunotherapy programs, revealing that three Phase 2 trials are advancing towards significant clinical milestones in 2024. Dr. Andrea Pfeifer,

Elektrofi, Inc., a company specializing in biopharmaceutical formulation technology, has recently unveiled a global research collaboration and licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson